Refinement of breast cancer classification by molecular characterization of histological special types

Journal of Pathology

Volumn 216, Issue 2, 2008, Pages 141-150

  Weigelt, B ^a,e   Horlings, H M ^a   Kreike, B ^a   Hayes, M M ^b,c   Hauptmann, M ^a   Wessels, L F A ^a   De Jong, D ^a   Van De Vijver, M J ^a,d   Van't Veer, L J ^a   Peterse, J L ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Breast cancer; Expression profiling; Histological classification; Molecular subtypes

Indexed keywords

MOLECULAR MARKER; TRANSCRIPTOME; TUMOR MARKER;

ADENOID CYSTIC CARCINOMA; APOCRINE CARCINOMA; ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CLUSTER ANALYSIS; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GIANT CELL; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LUNG CARCINOMA; MEDULLARY CARCINOMA; METAPLASIA; MUCINOUS CARCINOMA; NEUROENDOCRINE TUMOR; ONCOGENE NEU; OSTEOCLAST; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 53149133527     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2407     Document Type: Article

References (43)

1. Tavassoli FA, Devilee P. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon, 2003.
2. Schnitt SJ, Guidi AJ. Pathology of invasive breast cancer. In Diseases of the Breast (2nd edn), Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Lippincott Williams & Wilkins: Philadelphia, 2004; 541-584.
3. Page DL. Special types of invasive breast cancer, with clinical implications. Am J Surg Pathol 2003;27:832-835.
4. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.
5. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874.
6. Van't Veer LJ. Dai H. van de Vijver MJ. He YD, Man AA. Mao M. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.
7. Van de Vijver MJ. He YD, vant Veer LJ. Dai H. Hart AA. Voskuil DW. et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
8. Paik S, Shak S, Tang G, Kim C. Baker J, Cronin M. et al. A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N Engl J Med 2004;351:2817-2826.
9. Capella C, Kusebi V, Mann B, Azzopardi JG. Endocrine differentiation in mucoid carcinoma of the breast. Histopathlogy 1980;4:613-630.
10. Kononen J. Bubendorf L. Kallioniemeni A. Bärlund M. Schraml P. Leighton S. et al. Tissue microarrays for highthroughput molecular profiling of tumor specimens. Nature Med 1998;4:844-847.
11. Siegel S, Castellan NJ Jr. In Nonparametric Statistics for the Behavioral Sciences (2nd edn). McGraw-Hill: London, 1988: 206-216.
12. Yang Y, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002;30:e15.
13. Weng L, Dai H, Zhan Y, He Y, Stepaniants SB, Bassett DE. Rosetta error model for gene expression analysis. Bioinformatics 2006;22:1111- 1121.
14. Eisen M, Spellman P, Brown P, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-14868.
15. Hu Z. Fan C, Oh D, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7:96.
16. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-569.
17. Cheuk W, Chan JK. Subcellular localization of immunohistochemical signals: knowledge of the ultrastructural or biologic features of the antigens helps predict the signal localization and proper interpretation of immunostains. Int J Surg Pathol 2004;12:185-206.
18. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001;61:5979-5984.
19. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005;24:4660-4671.
20. Azoulay S, Lae M, Freneaux P, Merle S, Al Ghuzlan A, Chnecker C, et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favourable outcome. Mod Pathol 2005;18:1623-1631.
21. Arpino G, Clark GM, Mohsin S, Bardou VJ, Elledge RM. Adenoid cystic carcinoma of the breast: molecular markers. treatment, and clinical outcome. Cancer 2002;94:2119-2127.
22. Mathieu MC, Rouzier R, Llombart-Cussac A, Sideris L, Koscielny S, Travagli JP, et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 2004;40:342-351.
23. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-679.
24. Marchio C, Iravani M, Natrajan R, Lambros M, Savage K, Tamber N, et al. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol 2008;215:398-410.
25. Esposito NN, Chivukula M, Dabbs DJ. The ductal phenotypic expression of the E-cadherin/eatenin complex in tubulolobular carcinoma of the breast: an immunohistochemical and clinicopathologic study. Mod Pathol 2007;20:130-138.
26. Abdel-Falah TM, Powe DG, Hodi Z. Lee AH. Reis-Filho JS. Ellis IO. High frequency of coexistence of columnar cell lesions. lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol 2007;31:417-426.
27. Husebi V, Magalhaes F, Azzopardi JG. Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum Pathol 1992;23:655-662.
28. Nishizaki T, Chew K, Chu L, Isola J, Kallioniemi A, Weidner N, et al. Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer 1997;74:513-517.
29. Simpson PT, Reis-Filho JS, Lambros MBK, Jones C, Steele D, Mackay A, et al. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol 2008;215:231-244.
30. Reis-Filho JS, Simpson PT, Jones C, Steele D, Mackay A, Iravani M, et al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol 2005;207:1-13.
31. Weidner N, Semple JP. Pleomorphic variant of lobular carcinoma of the breast. Hum Pathol 1992;23:1167-1171.
32. de Visser K, Eichten A, Coussens L, Paradoxical roles of the immune system during cancer development. Nature Rev Cancer 2006;6:24-37.
33. Yakirevich E, Izhak OB, Rennert G, Kovacs ZG, Resnick MB. Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast. Mod Pathol 1999;12:1050-1056.
34. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adelaide J, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006;66:4636-4644.
35. Taplin ME. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 2007;4:236-244.
36. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Bartelink H, van de Vijver MJ. Gene expression profiling and histopathological characterization of triple negative/basal-like breast carcinomas. Breast Cancer Res 2007;9:R65.
37. Fadare O, Tavassoli FA. The phenotypic spectrum of basallike breast cancers: a critical appraisal. Adv Anat Pathol 2007;14:358-373.
38. Fulford LG, Reis-Filho JS, Ryder K, Jones C, Gillett CE, Hanby A, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 2007;9:R4.
39. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-2334.
40. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-1281.
41. Reis-Filho JS, Milanezi F, Steele D, Savage K, Simpson PT, Nesland JM, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006;49:10-21.
42. Jacquemier J, Padovani L, Rabayrol L, Lakhani SR, Penault-Llorca F, Denoux Y, et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Path 2005;207:260-268.
43. Vincent-Salomon A, Gruel N, Lucchesi C, MacGrogan G, Dendale R, Sigal-Zafrani B, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007;9:R24.